167 related articles for article (PubMed ID: 35887290)
1. Delivery of mGluR5 siRNAs by Iron Oxide Nanocages by Alternating Magnetic Fields for Blocking Proliferation of Metastatic Osteosarcoma Cells.
Kang MA; Rao PP; Matsui H; Mahajan SS
Int J Mol Sci; 2022 Jul; 23(14):. PubMed ID: 35887290
[TBL] [Abstract][Full Text] [Related]
2. Magnetically Induced Brownian Motion of Iron Oxide Nanocages in Alternating Magnetic Fields and Their Application for Efficient siRNA Delivery.
Kang MA; Fang J; Paragodaarachchi A; Kodama K; Yakobashvili D; Ichiyanagi Y; Matsui H
Nano Lett; 2022 Nov; 22(22):8852-8859. PubMed ID: 36346801
[TBL] [Abstract][Full Text] [Related]
3. Osteosarcoma cell proliferation and survival requires mGluR5 receptor activity and is blocked by Riluzole.
Liao S; Ruiz Y; Gulzar H; Yelskaya Z; Ait Taouit L; Houssou M; Jaikaran T; Schvarts Y; Kozlitina K; Basu-Roy U; Mansukhani A; Mahajan SS
PLoS One; 2017; 12(2):e0171256. PubMed ID: 28231291
[TBL] [Abstract][Full Text] [Related]
4. Osteosarcoma growth suppression by riluzole delivery via iron oxide nanocage in nude mice.
Raghubir M; Rahman CN; Fang J; Matsui H; Mahajan SS
Oncol Rep; 2020 Jan; 43(1):169-176. PubMed ID: 31789402
[TBL] [Abstract][Full Text] [Related]
5. Formulated siRNAs targeting Rankl prevent osteolysis and enhance chemotherapeutic response in osteosarcoma models.
Rousseau J; Escriou V; Lamoureux F; Brion R; Chesneau J; Battaglia S; Amiaud J; Scherman D; Heymann D; Rédini F; Trichet V
J Bone Miner Res; 2011 Oct; 26(10):2452-62. PubMed ID: 21713988
[TBL] [Abstract][Full Text] [Related]
6. Nanoscale polysaccharide derivative as an AEG-1 siRNA carrier for effective osteosarcoma therapy.
Wang F; Pang JD; Huang LL; Wang R; Li D; Sun K; Wang LT; Zhang LM
Int J Nanomedicine; 2018; 13():857-875. PubMed ID: 29467575
[TBL] [Abstract][Full Text] [Related]
7. Effects of combined c-myc and Bmi-1 siRNAs on the growth and chemosensitivity of MG-63 osteosarcoma cells.
Xie X; Ye Z; Yang D; Tao H
Mol Med Rep; 2013 Jul; 8(1):168-72. PubMed ID: 23685757
[TBL] [Abstract][Full Text] [Related]
8. SiRNA-mediated silencing of beta-catenin suppresses invasion and chemosensitivity to doxorubicin in MG-63 osteosarcoma cells.
Zhang F; Chen A; Chen J; Yu T; Guo F
Asian Pac J Cancer Prev; 2011; 12(1):239-45. PubMed ID: 21517265
[TBL] [Abstract][Full Text] [Related]
9. siRNA targeting TCTP suppresses osteosarcoma cell growth and induces apoptosis in vitro and in vivo.
Shen JH; Qu CB; Chu HK; Cui MY; Wang YL; Sun YX; Song YD; Li G; Shi FJ
Biotechnol Appl Biochem; 2016; 63(1):5-14. PubMed ID: 25522670
[TBL] [Abstract][Full Text] [Related]
10. [Expression of Ether à go-go 1 and its molecular mechanism of regulating the malignant phenotype of osteosarcoma].
Chen ZD; Liu QJ; Zeng WR; Wu XY; Lin B; Wu J
Zhonghua Zhong Liu Za Zhi; 2016 Nov; 38(11):818-825. PubMed ID: 27998439
[No Abstract] [Full Text] [Related]
11. In vivo self-assembly and delivery of VEGFR2 siRNA-encapsulated small extracellular vesicles for lung metastatic osteosarcoma therapy.
Yu L; Fan G; Wang Q; Zhu Y; Zhu H; Chang J; Wang Z; Zhan S; Hua X; She D; Huang J; Wang Y; Zhao J; Zhang CY; Chen X; Zhou G
Cell Death Dis; 2023 Sep; 14(9):626. PubMed ID: 37739958
[TBL] [Abstract][Full Text] [Related]
12. siRNAs target sites selection of ezrin and the influence of RNA interference on ezrin expression and biological characters of osteosarcoma cells.
Shang X; Wang Y; Zhao Q; Wu K; Li X; Ji X; He R; Zhang W
Mol Cell Biochem; 2012 May; 364(1-2):363-71. PubMed ID: 22286748
[TBL] [Abstract][Full Text] [Related]
13. Targeting hedgehog-GLI-2 pathway in osteosarcoma.
Yang W; Liu X; Choy E; Mankin H; Hornicek FJ; Duan Z
J Orthop Res; 2013 Mar; 31(3):502-9. PubMed ID: 22968906
[TBL] [Abstract][Full Text] [Related]
14. Inhibitory effects of VEGF-siRNA mediated by adenovirus on osteosarcoma-bearing nude mice.
Gao YS; Mei J; Tong TL; Hu M; Xue HM; Cai XS
Cancer Biother Radiopharm; 2009 Apr; 24(2):243-7. PubMed ID: 19409047
[TBL] [Abstract][Full Text] [Related]
15. Functional genome screen for therapeutic targets of osteosarcoma.
Yamaguchi U; Honda K; Satow R; Kobayashi E; Nakayama R; Ichikawa H; Shoji A; Shitashige M; Masuda M; Kawai A; Chuman H; Iwamoto Y; Hirohashi S; Yamada T
Cancer Sci; 2009 Dec; 100(12):2268-74. PubMed ID: 19725836
[TBL] [Abstract][Full Text] [Related]
16. [Knockdown of cyclin A2 expression by small interfering RNA in MG-63 cells].
Liu Y; Ding JY; Shen WL; Zhao X; Fan SW
Zhonghua Zhong Liu Za Zhi; 2007 Sep; 29(9):670-5. PubMed ID: 18246796
[TBL] [Abstract][Full Text] [Related]
17. Leptocarpin Suppresses Proliferation, Migration, and Invasion of Human Osteosarcoma by Targeting Type-1 Insulin-Like Growth Factor Receptor (IGF-1R).
Zheng SW; Wan WG; Miao HX; Tang R; Wang B; Huang QZ; Liu WL; Zheng JP; Chen CQ; Zhong HB; Li SF; Sun CH
Med Sci Monit; 2017 Aug; 23():4132-4140. PubMed ID: 28844074
[TBL] [Abstract][Full Text] [Related]
18. Downregulation of MCT1 inhibits tumor growth, metastasis and enhances chemotherapeutic efficacy in osteosarcoma through regulation of the NF-κB pathway.
Zhao Z; Wu MS; Zou C; Tang Q; Lu J; Liu D; Wu Y; Yin J; Xie X; Shen J; Kang T; Wang J
Cancer Lett; 2014 Jan; 342(1):150-8. PubMed ID: 24012639
[TBL] [Abstract][Full Text] [Related]
19. Histone deacetylase inhibition prevents the growth of primary and metastatic osteosarcoma.
McGuire JJ; Nerlakanti N; Lo CH; Tauro M; Utset-Ward TJ; Reed DR; Lynch CC
Int J Cancer; 2020 Nov; 147(10):2811-2823. PubMed ID: 32599665
[TBL] [Abstract][Full Text] [Related]
20. Polyphyllin I suppresses human osteosarcoma growth by inactivation of Wnt/β-catenin pathway in vitro and in vivo.
Chang J; Li Y; Wang X; Hu S; Wang H; Shi Q; Wang Y; Yang Y
Sci Rep; 2017 Aug; 7(1):7605. PubMed ID: 28790389
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
